Cancer Trials: Funding Shortages Force Patients to Travel for Treatment

The promise of advanced cancer treatment, and even potential cures, is facing a significant hurdle in Ireland: uneven access to clinical trials. A recent hearing of the Oireachtas Committee on Further and Higher Education revealed a stark disparity in funding for cancer research, leaving patients in some regions traveling long distances – or missing out altogether – on potentially life-saving opportunities. The core issue, as highlighted by those working within the system, isn’t a lack of dedicated professionals, but a precarious funding model and a failure to integrate research fully into long-term workforce planning.

Regional Disparities in Trial Access

The imbalance in funding is particularly acute when comparing the east of the country to other regions. Between 2021 and 2026, €10.8 million in public funding was allocated to cancer trial research programmes in the east. In contrast, the HSE West and North West region received just €600,000, with a similar amount allocated to Limerick. Dr. Veronica McInerney, cancer clinical trials programme manager for the HSE West and North West region, emphasized the limited impact of such funding. “That doesn’t buy an awful lot of manpower,” she told the committee. This shortfall translates directly into difficulties recruiting and retaining the specialist staff – nurses, radiation therapists, and researchers – needed to conduct trials effectively.

The consequences are tangible. Patients in areas like Tullamore, County Offaly, are being forced to travel to Dublin or Galway to participate in trials, adding significant burden to an already stressful time. This geographical barrier to access isn’t simply a matter of convenience; it can impact participation rates and the progress of vital research. The situation underscores a broader challenge: ensuring equitable access to healthcare innovation across Ireland.

The Precarity of Research Staffing

Beyond funding levels, the structure of research contracts is creating instability within the sector. Angela Clayton-Lea, CEO of Cancer Trials Ireland, explained that short-term, project-based contracts are hindering both recruitment, and retention. Even as Dublin-based staff may benefit from a consistent stream of projects, the temporary nature of their employment makes it difficult to secure mortgages or establish long-term financial stability. This creates a cycle where experienced professionals are less likely to remain in research roles, impacting the continuity and quality of trials.

This staffing challenge is further compounded by Ireland’s reliance on internationally trained nurses and midwives. Dr. Raymond Healy, director of registration at the Nursing and Midwifery Board of Ireland, reported that over 5,000 first-time registrants last year came from outside of Ireland, while the number of Irish-educated graduates joining the register has remained stable. The HSE is now heavily reliant on international staff, a situation that is not sustainable in the long term as other countries also face workforce shortages. While the number of Irish nurses seeking to work abroad has decreased recently (from 5,000 in 2023 to 1,800 last year), the overall dependence on foreign-trained professionals remains a significant concern.

The Evolution of Cancer Treatment and the Value of Trials

The importance of clinical trials in advancing cancer care was powerfully illustrated by Clayton-Lea, who cited the example of prostate cancer treatment. In the early 2000s, patients required 37 radiotherapy treatments; advancements developed through research have now reduced that number to just five. This demonstrates the tangible benefits of investing in clinical research and its direct impact on patient outcomes.

Clinical trials aren’t simply about identifying new drugs; they also focus on optimizing existing treatments. Even when a drug is approved for apply, further research is needed to determine the most effective dosage and schedule, minimizing side effects and maximizing benefits. This process of refinement is crucial for personalized cancer care, tailoring treatment plans to individual patient needs. Cancer Trials Ireland actively communicates the value of these trials, recently contributing data to the National Clinical Trials Oversight Group (NCTOG) report and working to align its own research with the group’s recommendations.

The Broader Context of Cancer Research Funding

The current situation highlights a fundamental issue: research is often viewed as an “add-on” rather than an integral component of healthcare delivery. As Dr. McInerney pointed out, the value of research needs to be explicitly articulated and incorporated into workforce planning. This requires a shift in perspective, recognizing that investment in research is not simply an expense, but a crucial investment in the future of cancer care.

The challenges facing cancer trials in Ireland are not unique. Globally, cancer deaths are projected to reach over 18 million per year by 2050, according to a recent study. This underscores the urgent necessitate for increased investment in cancer research and improved access to clinical trials worldwide.

Looking Ahead: Addressing the Systemic Issues

The Oireachtas Committee hearing served as a critical platform for raising awareness of these challenges. The next steps involve translating this awareness into concrete action. A key focus will be advocating for more sustainable funding models that prioritize long-term research capacity and address the regional disparities in access. Addressing the precarity of research contracts is essential for attracting and retaining skilled professionals. This could involve exploring options for more permanent positions or providing financial incentives to encourage long-term commitment to research roles.

ensuring equitable access to cancer clinical trials requires a systemic overhaul, integrating research into the core of healthcare planning and recognizing its vital role in improving patient outcomes. Continued dialogue between researchers, policymakers, and healthcare providers will be crucial in navigating these challenges and building a more robust and equitable cancer research landscape in Ireland.